RETN and metabolic syndrome: In humans, resistin strongly correlates with atherogenic dyslipidemia—characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol—and promotes hepatic very-low-density lipoprotein (VLDL) secretion via sterol regulatory element-binding protein-dependent mechanisms.